Monte Rosa Therapeutics Inc Cash Flow-to-Debt Ratio
Monte Rosa Therapeutics Inc cash flow-to-debt ratio. Monte Rosa Therapeutics Inc (GLUE) has a Cash Flow-to-Debt Ratio of -0.39x as of June 2026, meaning its operating cash flow of $-81.48 Million could theoretically repay 0% of its total liabilities ($211.03 Million) in one year. Check earnings quality score of Monte Rosa Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Monte Rosa Therapeutics Inc (2019–2025)
Cash flow-to-debt ratio of Monte Rosa Therapeutics Inc from 2019 to 2025. Historical debt coverage capacity for Monte Rosa Therapeutics Inc across 7 annual periods. Check GLUE capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Monte Rosa Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
Monte Rosa Therapeutics Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Monte Rosa Therapeutics Inc. For the full cash flow conversion analysis, see GLUE cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.11x | $-22.80 Million | $215.60 Million | ▼ -154.3% |
| 2024 | 0.19x | $42.00 Million | $215.80 Million | ▲ +155.3% |
| 2023 | -0.35x | $-43.80 Million | $124.50 Million | ▲ +73.0% |
| 2022 | -1.30x | $-92.47 Million | $70.98 Million | ▲ +58.7% |
| 2021 | -3.16x | $-59.36 Million | $18.81 Million | ▼ -1242.8% |
| 2020 | -0.23x | $-23.05 Million | $98.11 Million | ▲ +11.5% |
| 2019 | -0.27x | $-6.17 Million | $23.24 Million | — |